DarioHealth (DRIO) 10-Q 15 May 17 2017 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 12, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Entity Registrant Name	DarioHealth Corp.
Entity Central Index Key	1,533,998
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	DRIO
Entity Common Stock, Shares Outstanding		9,582,377

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 2,817	$ 1,093
Short-term bank deposits	235	225
Trade Receivables	482	226
Inventories	849	888
Other accounts receivable and prepaid expenses	702	504
Total current assets	5,085	2,936
LEASE DEPOSITS	44	35
PROPERTY AND EQUIPMENT, NET	856	901
Total assets	5,985	3,872
CURRENT LIABILITIES:
Trade payables	1,484	1,812
Other accounts payable and accrued expenses	1,240	1,113
Total current liabilities	2,724	2,925
LIABILITY RELATED TO WARRANTS	28	7,488
STOCKHOLDERS' EQUITY (DEFICIENCY)
Common Stock of $0.0001 par value -Authorized: 160,000,000 shares at March 31, 2017 (unaudited) and December 31, 2016; Issued and Outstanding: 7,976,521 and 5,713,383 shares at March 31, 2017 (unaudited) and December 31, 2016, respectively	6	6
Preferred Stock of $0.0001 par value -Authorized: 5,000,000 shares at March 31, 2017 (unaudited) and December 31, 2016; Issued and Outstanding: None at March 31, 2017 (unaudited) and December 31, 2016	0	0
Additional paid-in capital	54,945	48,413
Accumulated deficit	(51,718)	(54,960)
Total stockholders' equity (deficiency)	3,233	(6,541)
Total liabilities and stockholders' equity (deficiency)	$ 5,985	$ 3,872

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	160,000,000	160,000,000
Common stock, shares issued	7,976,521	5,713,383
Common stock, shares, outstanding	7,976,521	5,713,383
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Temporary Equity, Shares Issued	0	0
Temporary Equity, Shares Outstanding	0	0

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE PROFIT (LOSS) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues	$ 1,007	$ 568
Cost of revenues	901	670
Gross profit (loss)	106	(102)
Operating expenses:
Research and development	469	397
Sales and marketing	1,825	519
General and administrative	2,017	905
Total operating expenses	4,311	1,821
Operating loss	(4,205)	(1,923)
Financial income (expenses), net:
Revaluation of warrants	7,460	(432)
Other financial expense, net	(13)	(13)
Total financial income (expenses), net	7,447	(445)
Net profit (loss)	3,242	(2,368)
Deemed dividend related to Series A Preferred Stock exchange agreement	0	455
Net profit (loss) attributable to holders of Common Stock	$ 3,242	$ (2,823)
Net profit (loss) per share
Basic and diluted profit (loss) per share (in dollars per share)	$ 0.45	$ (0.77)
Weighted average number of Common Stock used in computing basic and diluted net profit (loss) per share (in shares)	7,195,801	3,652,474

STATEMENTS OF CHANGES IN STOCKH

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY) - USD ($) $ in Thousands	Total		Common Stock [Member]		Additional Paid-in Capital [Member]	Accumulated deficit [Member]
Balance at Dec. 31, 2015	$ (1,580)		$ 5		$ 41,769	$ (43,354)
Balance (in shares) at Dec. 31, 2015			2,911,788
Issuance of Common Stock in March 2016 Public Offering, net of issuance cost	1,572		$ 1		1,571	0
Issuance of Common Stock in March 2016 Public Offering, net of issuance cost (in shares)			1,333,333
Issuance of Common Stock in March 2016 Private Placement, net of issuance cost	828		$ 0	[1]	828	0
Issuance of Common Stock in March 2016 Private Placement, net of issuance cost (in shares)			599,999
Issuance of Common Stock in January 2016 to service provider	37		$ 0	[1]	37	0
Issuance of Common Stock in January 2016 to service provider (in shares)			5,556
Payment for executives, employee and directors under Salary Program	310		$ 0	[1]	310	0
Payment for executives, employee and directors under Salary Program (in shares)			57,910
Issuance of Common Stock in March 2016 to officer	86		$ 0	[1]	86	0
Issuance of Common Stock in March 2016 to officer (in shares)			20,000
Exercise of warrants into Common Stock, net of issuance cost	210		$ 0	[1]	210	0
Exercise of warrants into Common Stock, net of issuance cost (in shares)			77,019
Exercise of non plan options	0	[1]	$ 0	[1]	0	0
Exercise of non plan options (in shares)			84,106
Deemed dividend related to Series A Preferred Stock exchange agreement into Common Stock in March 2016	0		$ 0		455	(455)
Deemed dividend related to Series A Preferred Stock exchange agreement into Common Stock in March 2016 (in shares)			124,737
Deemed dividend related to extension of July 2015 Series A warrants in July 2016	0		$ 0		265	(265)
Conversion of Series A Preferred Stock into Common Stock	2,277		$ 0	[1]	2,277	0
Conversion of Series A Preferred Stock into Common Stock (in shares)			498,935
Stock-based compensation	605		$ 0		605	0
Net loss	(10,887)		0		0	(10,887)
Balance at Dec. 31, 2016	(6,541)		$ 6		48,413	(54,960)
Balance (in shares) at Dec. 31, 2016			5,713,383
Issuance of Common Stock in January 2017 Private Placement, net of issuance cost	2,886		$ 0	[1]	2,886	0
Issuance of Common Stock in January 2017 Private Placement, net of issuance cost (in shares)			1,113,922
Payment for executives, employee and directors under Salary Program	250		$ 0	[1]	250	0
Payment for executives, employee and directors under Salary Program (in shares)			77,891
Issuance of Common Stock in January 2017 to Employees	1,198		$ 0	[1]	1,198	0
Issuance of Common Stock in January 2017 to Employees (in shares)			352,257
Issuance of Common Stock in January 2017 to consultants and service provider	49		$ 0	[1]	49	0
Issuance of Common Stock in January 2017 to consultants and service provider (in shares)			11,553
Conversion of Series A Preferred Stock into Common Stock	0
Issuance of Common Stock in March 2017 Private Placement, net of issuance cost	1,878		$ 0	[1]	1,878	0
Issuance of Common Stock in March 2017 Private Placement, net of issuance cost (in shares)			707,515
Stock-based compensation	271		$ 0		271	0
Net loss	3,242		0		0	3,242
Balance at Mar. 31, 2017	$ 3,233		$ 6		$ 54,945	$ (51,718)
Balance (in shares) at Mar. 31, 2017			7,976,521
[1]	Represents an amount lower than $1.

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net profit (loss)	$ 3,242	$ (2,368)
Adjustments required to reconcile net profit (loss) to net cash used in operating activities:
Stock-based compensation and Common Stock to service providers	1,585	324
Depreciation	44	102
Increase is trade receivables	(256)	0
Decrease (increase) in accounts receivables and prepaid expenses	(210)	10
Decrease (increase) in inventories	39	(404)
Decrease in trade payables	(328)	(422)
Decrease in deferred revenues	0	(23)
Increase in other accounts payable and accrued expenses	262	244
Change in fair value of warrants to purchase shares of Common stock	(7,460)	432
Net cash used in operating activities	(3,082)	(2,105)
Cash flows from investing activities:
Maturity of (investment in) lease deposits	(9)	8
Purchase of property and equipment	0	(35)
Net cash used in investing activities	(9)	(27)
Cash flows from financing activities:
Proceeds from issuance of Common Stock and warrants, net of issuance cost	4,816	7,538
Proceeds from exercise of options and warrants	0	190
Net cash provided by financing activities	4,816	7,728
Increase in cash and cash equivalents	1,724	5,596
Cash and cash equivalents at the beginning of the period	1,093	2,671
Cash and cash equivalents at the end of the period	2,817	8,267
Non-cash investing and financing activities:
Conversion of Series A Preferred Stock to Common Stock	0	2,277
Payment for directors and management under Shares for Cash Program	$ 183	$ 51

GENERAL

GENERAL	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1:- GENERAL a. DarioHealth Corp. (formerly LabStyle Innovations Corp.) (the “Company”) was incorporated in Delaware and commenced operations on August 11, 2011. The Company is a digital health (mHealth) company that is developing and commercializing a patented and proprietary technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company’s flagship product, Dario TM TM TM b. The Company’s wholly owned subsidiary, LabStyle Innovation Ltd. (“Ltd.” or “Subsidiary”), was incorporated and commenced operations on September 14, 2011 in Israel. Its principal business activity is to hold the Company’s intellectual property and to perform research and development, manufacturing, marketing and other business activities. Ltd. has a wholly-owned subsidiary, LabStyle Innovations US LLC, a Delaware limited liability company (“LabStyle US”), which was established in 2014, however it has not started its operations to date. c. During the three months ended March 31, 2017, the Company incurred operating losses and negative cash flows from operating activities amounting to $4,205 and $3,082, respectively. The Company will be required to obtain additional liquidity resources in order to support the commercialization of its products and maintain its research and development activities. The Company is addressing its liquidity needs by seeking additional funding from public and/or private sources and by ramping up its commercial sales. There are no assurances, however, that the Company will be able to obtain an adequate level of financial resources that are required for the short and long-term development and commercialization of its product. According to management estimates, the Company has sufficient liquidity resources to continue its planned activity into January 2018. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. d. On March 4, 2016, the Company's Common Stock and warrants were approved for listing on NASDAQ Capital Market under the symbols “DRIO” and “DRIOW,” respectively .

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	SIGNIFICANT ACCOUNTING POLICIES The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2016 are applied consistently in these unaudited interim consolidated financial statements.

UNAUDITED INTERIM FINANCIAL STA

UNAUDITED INTERIM FINANCIAL STATEMENTS	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting [Text Block]	NOTE 3:- UNAUDITED INTERIM FINANCIAL STATEMENTS The accompanying unaudited interim consolidated financial statements as of March 31, 2017, have been prepared in accordance with U.S. generally accepted accounting principles and standards of the Public Company Accounting Oversight Board for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for a fair presentation of the Company's consolidated financial position as of March 31, 2017, and the Company's consolidated results of operations and the Company's consolidated cash flows for the three months ended March 31, 2017. Results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	NOTE 4: - INVENTORIES March 31, December 31, 2017 2016 Unaudited Raw materials $ 424 $ 431 Finished products 425 457 $ 849 $ 888 During the three months’ period ended March 31, 2 0 0

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 5: - COMMITMENTS AND CONTINGENT LIABILITIES From time to time the Company is involved in claims and legal proceedings. The Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss.

STOCKHOLDERS' EQUITY (DEFICIENC

STOCKHOLDERS' EQUITY (DEFICIENCY)	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 6:- STOCKHOLDERS' EQUITY (DEFICIENCY) a. On January 9, 2017, the Company commenced a private placement offering of up to $ 5,100 1,821,437 0.0001 1,821,437 5 1,113,922 1,113,922 3,119 2,886 707,515 707,515 1,981 1,878 b. In January 2017, 77,891 c. In January 10, 2017, 6,553 34,050 0.0001 d. In January and February 2017, the Company's Compensation Committee of the Board of Directors approved the grants of 367,257 211,492 286,229 21,000 3.202 4.121 three six e. Stock option compensation: Number of Weighted Weighted Aggregate options price contractual life value $ Years $ Options outstanding at beginning of year 583,334 16.53 4.87 7 Options granted 542,771 3.03 Options exercised - - Options expired (12,158) 5.29 Options forfeited (2,223) 5.76 Options outstanding at period end (unaudited) 1,111,724 10.08 5.22 109 Options vested and expected to vest at period end (unaudited) 998,923 10.62 5.19 109 Exercisable at period end (unaudited) 430,428 19.94 4.66 109 The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company's closing stock price on the last day of the first quarter of 2017 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on March 31, 2017. This amount is impacted by the changes in the fair market value of the Common Stock. As of March 31, 2017, the total amount of unrecognized stock-based compensation expense was approximately $ 1,200 1.3 Three months ended March 31, 2017 2016 Unaudited Cost of revenues $ 54 $ 9 Research and development 71 26 Sales and marketing 123 31 General and administrative 1,337 258 Total stock-based compensation expenses $ 1,585 $ 324

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 7:- FAIR VALUE MEASUREMENTS Accounting Standards Codification 820, “Fair Value Measurements and Disclosures” (“ASC 820”), defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. ASC 820 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument's categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. ASC 820 establishes three levels of inputs that may be used to measure fair value: Level 1 - quoted prices in active markets for identical assets or liabilities; Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. On September 23, 2014, the Company consummated the September 2014 Private Placement. The warrants issued in the September 2014 Private Placement contain a net settlement cash feature and liquidated damages penalties and therefore the Company accounts for such warrants as a liability according to the provisions of ASC 815-40 “Contracts in entity’s own equity,” and re-measures such liability using the Binomial option-pricing model as described below. March 31, 2017 Risk-free interest rate (1) 1.15 % Expected volatility (2) 91.75 % Expected life (in years) (3) 1.48 Expected dividend yield (4) 0 % Fair value per warrant $ 0.49 (1) Risk-free interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury bonds. (2) Expected volatility - was calculated based on actual historical stock price movements of the Company together with companies in the same industry over a term that is equivalent to the expected term of the option. (3) Expected life - the expected life was based on the expiration date of the warrants. (4) Expected dividend yield - was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends to its shareholders in the future. (5) The changes in Level 3 liabilities associated with the warrants are measured at fair value on a recurring basis. Fair value Balance at December 31, 2016 $ 7,488 Change in fair value of warrants during the period (7,460) Balance at March 31, 2017 (unaudited) $ 28

FINANCIAL INCOME (EXPENSES), NE

FINANCIAL INCOME (EXPENSES), NET	3 Months Ended
	Mar. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Text Block]	NOTE 8:- FINANCIAL INCOME (EXPENSES), NET Three months ended March 31, 2017 2016 Unaudited Bank charges $ (5) $ (4) Foreign currency translation adjustments (8) (9) Change in fair value of warrants 7,460 (432) Total financial income (expenses), net $ 7,447 $ (455)

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 9:- SUBSEQUENT EVENTS On April 5, 2017, the Company closed a public offering (the “Public Offering”) of 1,450,000 3.10 In addition, the Company granted to the underwriters in the Public Offering a 45-day option period to purchase up to 217,500 4.185 36,250 3.875

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	March 31, December 31, 2017 2016 Unaudited Raw materials $ 424 $ 431 Finished products 425 457 $ 849 $ 888

STOCKHOLDERS' EQUITY (DEFICIE17

STOCKHOLDERS' EQUITY (DEFICIENCY) (Tables)	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Transactions related to the grant of options to employees, directors and non-employees under the above plans during the three-month period ended March 31, 2017 were as follows: Number of Weighted Weighted Aggregate options price contractual life value $ Years $ Options outstanding at beginning of year 583,334 16.53 4.87 7 Options granted 542,771 3.03 Options exercised - - Options expired (12,158) 5.29 Options forfeited (2,223) 5.76 Options outstanding at period end (unaudited) 1,111,724 10.08 5.22 109 Options vested and expected to vest at period end (unaudited) 998,923 10.62 5.19 109 Exercisable at period end (unaudited) 430,428 19.94 4.66 109
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	The total compensation cost related to all of the Company's equity-based awards recognized during the three-month period ended March 31, 2017 and 2016 was comprised as follows: Three months ended March 31, 2017 2016 Unaudited Cost of revenues $ 54 $ 9 Research and development 71 26 Sales and marketing 123 31 General and administrative 1,337 258 Total stock-based compensation expenses $ 1,585 $ 324

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Warrants Fair Value [Table Text Block]	In estimating the warrants' fair value, the Company used the following assumptions: March 31, 2017 Risk-free interest rate (1) 1.15 % Expected volatility (2) 91.75 % Expected life (in years) (3) 1.48 Expected dividend yield (4) 0 % Fair value per warrant $ 0.49 (1) Risk-free interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury bonds. (2) Expected volatility - was calculated based on actual historical stock price movements of the Company together with companies in the same industry over a term that is equivalent to the expected term of the option. (3) Expected life - the expected life was based on the expiration date of the warrants. (4) Expected dividend yield - was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends to its shareholders in the future. (5) The changes in Level 3 liabilities associated with the warrants are measured at fair value on a recurring basis.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following tabular presentation reflects the components of the liability associated with such warrants as of March 31, 2017: Fair value Balance at December 31, 2016 $ 7,488 Change in fair value of warrants during the period (7,460) Balance at March 31, 2017 (unaudited) $ 28

FINANCIAL INCOME (EXPENSES), 19

FINANCIAL INCOME (EXPENSES), NET (Tables)	3 Months Ended
	Mar. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	Three months ended March 31, 2017 2016 Unaudited Bank charges $ (5) $ (4) Foreign currency translation adjustments (8) (9) Change in fair value of warrants 7,460 (432) Total financial income (expenses), net $ 7,447 $ (455)

GENERAL (Details Textual)

GENERAL (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Organization And Presentation Of Financial Statements [Line Items]
Operating Income (Loss)	$ 4,205	$ 1,923
Net Cash Provided by (Used in) Operating Activities	$ 3,082	$ 2,105

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Inventory [Line Items]
Raw materials	$ 424	$ 431
Finished products	425	457
Inventory, Net	$ 849	$ 888

INVENTORIES (Details Textual)

INVENTORIES (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Inventory [Line Items]
Inventory Write-down	$ 22	$ 315

STOCKHOLDERS' EQUITY (DEFICIE23

STOCKHOLDERS' EQUITY (DEFICIENCY) (Details) - Employee Stock Option [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding at beginning of year, Number of options	583,334
Options granted, Number of options	542,771
Options exercised, Number of options	0
Options expired, Number of options	(12,158)
Options forfeited, Number of options	(2,223)
Options outstanding at end of year, Number of options	1,111,724	583,334
Options vested and expected to vest at end of year, Number of options	998,923
Exercisable at end of year, Number of options	430,428
Options outstanding at beginning of year, Weighted average exercise price	$ 16.53
Options granted, Weighted average exercise price	3.03
Options exercised, Weighted average exercise price	0
Options expired, Weighted average exercise price	5.29
Options forfeited, Weighted average exercise price	5.76
Options outstanding at end of year, Weighted average exercise price	10.08	$ 16.53
Options vested and expected to vest at end of year, Weighted average exercise price	10.62
Exercisable at end of year, Weighted average exercise price	$ 19.94
Options outstanding at, Weighted average remaining contractual life	5 years 2 months 19 days	4 years 10 months 13 days
Options vested and expected to vest at end of year, Weighted average remaining contractual life	5 years 2 months 8 days
Exercisable at end of year, Weighted average remaining contractual life	4 years 7 months 28 days
Options outstanding, Aggregate Intrinsic value	$ 109	$ 7
Options vested and expected to vest at end of year, Aggregate Intrinsic value	109
Exercisable at end of year, Aggregate Intrinsic value	$ 109

STOCKHOLDERS' EQUITY (DEFICIE24

STOCKHOLDERS' EQUITY (DEFICIENCY) (Details 1) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expenses	$ 1,585	$ 324
Cost of revenues [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expenses	54	9
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expenses	71	26
Sales, Marketing and pre-production costs [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expenses	123	31
General and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expenses	$ 1,337	$ 258

STOCKHOLDERS' EQUITY (DEFICIE25

STOCKHOLDERS' EQUITY (DEFICIENCY) (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Feb. 06, 2017	Jan. 11, 2017	Jan. 10, 2017	Feb. 28, 2017	Jan. 31, 2017	Jan. 09, 2017	Mar. 31, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Stock Issued During Period, Value, New Issues								$ 1,572
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options							$ 1,200
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition							1 year 3 months 18 days
Stock Issued During Period Shares New Issues February 2014						1,821,437
Proceeds from Issuance of Private Placement						$ 5,100
Common Stock, Par Or Stated Value Per Share							$ 0.0001	$ 0.0001
Equity Incentive Plan 2012 [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, New Issues			$ 6,553
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	34,050
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.0001
Officer [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				211,492
Board of Director and Officers [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross					77,891
Employees [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				286,229
Consultants [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				21,000
Employees Directors And Consultants [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				6 years
Stock Issued During Period, Shares, Share-based Compensation, Gross				367,257
Employees Directors And Consultants [Member] | Minimum [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 3.202
Employees Directors And Consultants [Member] | Maximum [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 4.121
Private Placement [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						1,821,437
Proceeds from Issuance of Private Placement						$ 3,119
Exercisable Term						5 years
Payments of Stock Issuance Costs						$ 2,886
Common Stock, Par Or Stated Value Per Share						$ 0.0001
Private Placement [Member] | Investor [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues						1,113,922
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						1,113,922
Securities Purchase Agreements [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues		707,515
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		707,515
Proceeds from Issuance of Private Placement						$ 1,981
Payments of Stock Issuance Costs						$ 1,878

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - Investors Warrants [Member] - September 2014 Private Placement [Member]	3 Months Ended
	Mar. 31, 2017$ / shares
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.15%	[1]
Expected volatility	91.75%	[2]
Expected life (in years)	1 year 5 months 23 days	[3]
Expected dividend yield	0.00%	[4]
Fair value per warrant	$ 0.49
[1]	Risk-free interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury bonds.
[2]	Expected volatility - was calculated based on actual historical stock price movements of the Company together with companies in the same industry over a term that is equivalent to the expected term of the option.
[3]	Expected life - the expected life was based on the expiration date of the warrants.
[4]	Expected dividend yield - was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends to its shareholders in the future.

FAIR VALUE MEASUREMENTS (Deta27

FAIR VALUE MEASUREMENTS (Details 1) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Balance at December 31, 2016	$ 7,488
Change in fair value of warrants during the period	(7,460)
Balance at March 31, 2017	$ 28

FINANCIAL INCOME (EXPENSES), 28

FINANCIAL INCOME (EXPENSES), NET (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Selected Statements Of Operations Data [Line Items]
Bank charges	$ (5)	$ (4)
Foreign currency translation adjustments	(8)	(9)
Change in fair value of warrants	7,460	(432)
Total financial income (expenses), net	$ 7,447	$ (445)

SUBSEQUENT EVENTS (Details Text

SUBSEQUENT EVENTS (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Apr. 05, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Stock Issued During Period, Value, New Issues		$ 1,572
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	1,450,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 3.875
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	36,250
Stock Issued During Period, Value, New Issues	$ 3,840
Shares Issued, Price Per Share	$ 3.10
Subsequent Event [Member] | Underwriting Agreement [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	217,500
Shares Issued, Price Per Share	$ 4.185